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Efficacy data were computed from all randomized trials (RT) that guided on-label
uses of bevacizumab (K-Ras mutated), panitumumab and cetuximab. Non- signif-
icant outcomes and toxicity as predictor of efficacy were excluded. Prices for drugs
in Spain were assumed to represent the best-value for each drug including all
possibilities to reduce pharmacy costs. For 1st line, median duration of therapy
reported by RT was used to calculate the final budget. 70kg and 1.7 m were used as
reference for patient dose calculations. RESULTS: We simulated 3 main scenarios
based on the possibilities of therapy for K-Ras wild type (wt) patients assuming that
all patients harboring a K-Ras mutated tumor received bevacizumab based chemo-
therapy. So, in scenario A K-Ras wt patients received weekly cetuximab combined
with FOLFOX, ORR reaches 54% and global cost per RR sums €20,026. Scenario B:
administering panitumumab-FOLFOX yields 51% ORR and € 19,861 per RR. Scenario
C: cetuximab biweekly combined with FOLFOX yields 54% and €19,726. ICER for
scenario A vs B is estimated at € 22,835 per additional response. ICER for scenario C
vs B is estimated at € 968 per additional response. CONCLUSIONS: First-line oxali-
patin combinations of cetuximab for wt and bevacizumab for mutated patients
optimize response rate rather than panitumumab and bevacizumab schedules.
Efficiency of this therapeutic approach could be improved with biweekly cetux-
imab administration. Marginal cost differences between cetuximab and panitu-
mumab therapies are exceeded by efficacy gap as measured by response rates in
RT.
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OBJECTIVES: An analysis recently evaluated hematologic responses among 126
Iraqi Ph CML-CP patients who were switched from Glivec (the beta crystalline
form of imatinib mesylate [IM]), to an alpha crystalline form, generic copy of ima-
tinib (IMgc). At the time of IMgc switch, patients had received IM for 50 months and
were at least in complete hematologic response (CHR). Three months post-switch,
18 (14%) and 4 (3%) patients progressed to accelerated phase (AP) and blast crisis
(BC), respectively. Six months post-switch, an additional 20 (16%) lost hematologic
response. A previously-published CML Markov model was adapted to compare over
50 years the projected life-years (LYs), progression-free life-years (PFLY), and qual-
ity-adjusted life-years (QALYs) of IM patients switched vs. not switched to IMgc.
METHODS: Patients entered the model after 50 months of IM therapy. At that time,
based on the IRIS trial results, patients were assumed to be distributed in CHR
(4.7%), partial (6.5%) and complete (88.9%) cytogenetic response. Patients remain-
ing on IM transitioned within these 3 responses levels and no hematologic re-
sponse, AP, BC, and death according to the original model probabilities. For pa-
tients switched to IMgc, transition rates were based exclusively on rates observed
in the Iraqi study (Scenario 1) or on the Iraqi study for the first 6 months and
thereafter on the original model (Scenario 2). Utilities were from the original model.
RESULTS: Patients remaining on IM were predicted to experience 15.71 LYs, 14.51
PFLYs, and 13.44 QALYs. Corresponding numbers for patients switched to IMgc
were 2.42 LYs, 1.13 PFLYs, 1.39 QALYs (in Scenario 1) and 11.44 LYs, 10.19 PFLYs, and
9.57 QALYs (in Scenario 2). Results were also sensitive to response distribution at
model entry. CONCLUSIONS: Switching from IM to an IMgc that does not have the
same properties may result in substantial loss of LYs, PFLYs, and QALYs.
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OBJECTIVES: Crizotinib, a tyrosine kinase anaplastic lymphoma kinase (ALK) in-
hibitor, represents a therapeutic alternative to patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC) that are ALK. This study aimed to
estimate the cost-effectiveness of crizotinib in the treatment of this group of pa-
tients compared to currently available chemotherapy schemes:
gemcitabinecisplatin (GC), pemetrexedcisplatin (PC) and docetaxelcisplatin
(DC), from the Mexican public payer’s perspective. METHODS: A mutually exclu-
sive, four-state Markov model was developed: stable without progression, stable
with response to treatment, disease progression and death (monthly transitions,
six-year timeframe, 5% discount rate). The model assess life-years gained and
direct medical costs (pre-treatment, drugs costs, drug administration, monitoring
and adverse event management), per each treatment (basecase GC), in terms of
ICER. Effectiveness data was extracted from published literature. Drug costs and
medical resources were extracted from Instituto Mexicano del Seguro Social data-
base. Crizotinib’s cost were provided by manufacturer (not listed yet in Mexican
formulary) and are expressed in 2012 US$. Univariate sensitivity analyses regard-
ing monthly acquisition cost and clinical efficacy of crizotinib were performed.
RESULTS: Crizotinib was the most effective alternative with 3.02 life-years gained,
compared with 1.55, 1.74 and 1.34 for GC, PC and DC, respectively. The cost of GC
was $15,792.3, while the incremental cost for PC, DC and crizotinib were $10,787.4,
$13,171 and $61,895.3, respectively. DC was dominated, while ICER for PC and cr-
izotinib were $56,775.9 and $42,105.6, respectively, being crizotinib a cost-effective
alternative. Results were sensible to changes in acquisition cost of crizotinib and
less sensible to changes in the probabilities of death and disease progression with
crizotinib. CONCLUSIONS: From the Mexican public payer’s perspective, crizotinib
would represent an opportunity for both, this group of patients, and health care
institutions to achieve better clinical results than GC, PC and DC, as well as minor
cost regarding PC.
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COST EFFECTIVENESS OF CYCLOPHOSPHAMIDE IN THE ADJUVANT
TREATMENT OF BREAST CANCER IN EUROPE: A MULTI-COUNTRY STUDY
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OBJECTIVES: Breast-cancer is the most frequent malignancy amongst women in
Europe and therefore represents a major public-health problem. The purpose of
this analysis was to estimate the cost-effectiveness of AT (doxorubicin, docetaxel)
compared with AC (doxorubicin, cyclophosphamide), CMF (cyclophosphamide,
methotrexat, 5-fluoruracil) and FEC (5-fluoruracil, epirubicin, cyclophosphamide)
administered as adjuvant therapy to women with node-positive breast-cancer
across four European countries (Spain, Italy, Germany and Belgium). METHODS:
We developed a multi-country Markov-model to simulate the long-term conse-
quences from initiation of adjuvant chemotherapy over 10 years. The model sim-
ulates the incidence of complications during chemotherapy (febrile neutropenia,
chemotherapy-induced nausea/vomiting, dose-reduction, dose-delay, grade 3/4
adverse events) and long-term consequences like local or distant-relapse, acute
myelogenous leukemia (AML), chronic heart failure and death. Monte-Carlo-sim-
ulation accounted for uncertainty. The model includes twelve health-states. Prob-
abilities were derived from clinical and epidemiological studies; direct costs (2011)
from published sources from the payer’s perspective. QALYs, life-years (LYs) and
costs were discounted at 5% p.a. RESULTS: Over a 10-year timeframe, costs asso-
ciated with AC are 13,266€, 14,826€, 15,699€ and 16,558€ for Spain, Italy, Germany
and Belgium, respectively. AC is associated with 5.85 QALYs (6.49 LYs). Costs for AT
amount to 15,362€ (Spain), 19,004€ (Italy), 19,768€ (Germany) and 20,625€ (Belgium)
and AT delivers a similar benefit to AC: 5.85 QALYs (6.50 LYs). The resulting oppor-
tunities for cost-savings with AC vs. AT are between 2,096€ (Spain) and 4,178€
(Italy). Costs associated with CMF are 14,145€ (Spain), 15,609€ (Italy), 16,411€ (Ger-
many) and 16,924€ (Belgium); 5.8 QALYs (6.4 LYs) are gained. AC dominates CMF.
FEC associated total costs are 15,138€ (Spain), 15,652€ (Italy), 17,431€ (Germany) and
17,492€ (Belgium). QALYs are 6.03 (6.81 LYs). FEC dominates AT in all four countries.
CONCLUSIONS: Cyclophosphamide-based regimens (FEC, AC and CMF) demon-
strate a better performance from cost-effectiveness perspective vs. AT in the four
European countries.
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OBJECTIVES: Renal cell carcinoma (RCC) accounts for approximately 2% of all can-
cers worldwide. Many patients present with advanced or unresectable disease, and
up to 30% of patients treated by nephrectomy for localized disease will relapse.
Improved care for patients with metastatic RCC (mRCC), including targeted thera-
pies have improved prognosis but have also increased drug costs. In this study, we
set out to study costs and outcomes in mRCC treatment using national registries
comprising all patients diagnosed with RCC in Sweden. METHODS: Two cohorts of
patients diagnosed with mRCC 2002-2005 and 2006-2008, representing patients
diagnosed pre- and post-TKI introduction respectively, were identified in the na-
tional Swedish Cancer Registry. A pre-defined algorithm was used to determine the
presence of mRCC. Through record linkage with the national registries for drug
prescriptions, hospital care, and causes of death, data on resource utilization and
survival was obtained. The Kaplan-Meier method was used to estimate survival,
using an exponential model to calculate the mean for 4.5 years - beyond the end of
the observation period. Costs were estimated in 2010 SEK (1 SEK  USD ($) 0.14),
using the Lin method to account for censoring. Sensitivity analysis was done to
better incorporate the cost of hospital dispensed drugs. RESULTS: Patients diag-
nosed post-TKI introduction (n1,217) had longer survival (median 1.08 compared
to 0.79 years, restricted mean 1.73 compared to 1.55, both p  0.001) compared to
patients diagnosed pre-TKI introduction (n1,536). Costs were higher for patients
more recently diagnosed: $52,601 versus $40,970. Pharmaceutical costs were
$12,418 higher in the post period but where slightly offset by lower inpatient care
costs. The cost per life-year gained (LYG) amounted to $64,616.CONCLUSIONS:The
study suggests that mRCC survival has improved in recent years while costs have
increased, resulting in a fairly modest cost per LYG in a Swedish setting.
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OBJECTIVES: To estimate the cost-effectiveness of maintenance therapy with oral
erlotinib (150mg/day) and BSC compared with BSC, in patients with advanced non-
small-cell lung cancer (NSCLC) EGFR WT and stable disease after completing four
cycles of first-line platinum-based chemotherapy. METHODS: A Markov model
including three health states (progression free survival, progression and death)
was developed to evaluate the cost per life year gained (LYG) of maintenance treat-
ment with erlotinib vs BSC from the Spanish National Healthcare System perspec-
tive. Clinical data inputs were based on the SATURN trial results. Resource utiliza-
tion related to each health state was estimated by a Spanish Expert Panel. Drug and
unitary costs were obtained from a Spanish database (€, 2012). The annual discount
rate applied was 3.0% for cost and outcomes. The simulation was carried out over
a 5 year time horizon and one-way deterministic and probabilistic sensitivity anal-
yses were conducted to assess the uncertainty around key input values. RESULTS:
In the prespecified subset of patients with EGFR WT and stable disease, the annual
cost per patient of erlotinib and placebo, including supportive care and adverse
events costs, was 23,912€ and 13,969€, respectively. Erlotinib also achieved a mean
gain of 1.40 life-years compared with the 1.12 LYG with placebo. The incremental
cost-effectiveness ratio of erlotinib relative to placebo was calculated to be 35,265 €
per LYG. Sensitivity analyses confirmed the robustness of the results.
CONCLUSIONS: In patients with advanced NSCLC EGFR WT and stable disease
after 4 cycles of chemotherapy, maintenance treatment with erlotinib is a thera-
peutic option that increases survival of patients and may be cost-effective vs BSC in
Spain.
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WITH BREAST CANCER AND FOR WHOM ANTHRACYCLINES ARE NOT
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OBJECTIVES:Metastatic breast cancer remains an incurable disease with a median
survival of about 2 years and essentially palliative treatment. Nab-paclitaxel is a
new formulation of paclitaxel, that is reduced at nano-scale level, in order to solve
its solubility problem without using organic solvents. It is indicated in the second
line of treatment for those patients for whom anthracyclines are controindicated.
Although in Italy an official cost-effectiveness threshold value is not identified, the
Italian Association of Health Economics (AIES) identifies a range from € 25.000 to €
40.000/QALY or LYG. The objective of the study is to evaluate the cost-effectiveness
of Nab-paclitaxel versus conventional paclitaxel in the Regional Health Service
(RHS) in second-line patients.METHODS: Survival data from the pivotal study were
used to calculate the Incremental cost-effectiveness Ratio (ICER). Both drugs were
administered every 3 weeks (Nab-paclitaxel300mg/m2, paclitaxel175mg/m2).
The maximum hospital wholesale price allowable for Nab-paclitaxel and regional
tender price for conventional paclitaxel were considered to calculate costs of treat-
ment. The analysis evaluated them from the perspective of the RHS, quantifying
only costs of chemotherapy, as other direct costs (i.e. staff, premedication, man-
aging adverse events) were not quantifiable or highly variable (conservative anal-
ysis). The cost of drug administration was not considered, since it was the same for
both drugs (6 administration). RESULTS: Therapy with Nab-paclitaxel versus pa-
clitaxel leads to an increase of the survival (0,186/years) and an increase of costs
( €6.525). The ICER is €35.077/LYG. CONCLUSIONS: Nab-paclitaxel versus conven-
tional paclitaxel showed an ICER €35.077/LYG. The limit of the analysis is related
to the choice of the comparator, that may not be the best therapeutic alternative.
Other alternatives could be weekly paclitaxel, vinorelbine, capecitabine and do-
cetaxel, for which, however, there are no clinical data emerging from direct com-
parisons.
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OBJECTIVES: Autologous peripheral blood stem cell (aPBSC) transplant is the stan-
dard of care for patients with multiple myeloma (MM) or non-Hodgkin’s lymphoma
(NHL) beyond first remission in Spain. Patients with peripheral blood CD34 10
cells/L are considered as poor mobilisers, and require alternative mobilisation
regimens to achieve a sufficient number of CD34 cells to undergo transplantation.
Those patients who collect 2x106 CD34 cell/kg will proceed to transplant. The
most common mobilization treatments currently used are GCSF alone or GCSF 
chemotherapy. The aim is to assess the cost-effectiveness of plerixafor  GCSF
compared to GCSF alone or GCSF chemotherapy, for mobilisation of CD34 cells
in patients with MM or NHL whose cells mobilise poorly from the perspective of the
Spanish National Healthcare System (NHS). METHODS: A cost-effectiveness anal-
ysis was performed using a semi-Markov process that embedded two decision
trees for aPBSC and continuation of care, from the NHS perspective. The Markov
model used three health states: well, remission and death and annual cycles in a
time horizon of 10 years. The mobilisation decision tree includes the preapheresis,
apheresis and transplantation pathways. The continuation of care includes the
most frequent therapies used after failing mobilisation or relapsing. The probabi-
listic sensitivity analysis was conducted to incorporate parameter uncertainties.
Outcomes were quality-adjusted life years (QALY) and costs expressed in € in 2012.
RESULTS: The base case analysis resulted in an incremental cost-effectiveness
ratio (ICER) for plerixafor GCSF versus GCSF alone of €19,787 for NHL and €30,476
for MM patients. When compared to GCSF  chemo, the ICER was €18,975 for NHL
and €27,718 for MM patients. Probabilistic sensitivity analysis on the key parame-
ters confirmed the robustness of the base case. CONCLUSIONS: Plerixafor  GCSF,
used in poor mobilisers patients, is a cost-effective strategy for both NHL and MM
patients in Spain.
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PHARMACOECONOMIC EVALUATION OF ACUTE MYELOID LEUKEMIA AND MDS
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AZACITIDINE IN THE RUSSIAN FEDERATION
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OBJECTIVES: To assess the cost-effectiveness of azacitidine in treatment of acute
myeloid leukemia and MDS syndromes in the Russian Federation. METHODS: To
conduct the cost-effectiveness analysis of acute myeloid leukemia and MDS syn-
dromes treatment we evaluated costs of diagnostics, treatment of the disease, side
effects and blood transfusions for azacitidine and low dose cytarabine. The efficacy
data of drugs (median survival-MS) was obtained from clinical trial AZA-001. MS for
azacitidine was 2,04 years and for low dose cytarabine - 1,28 years. Medical care
costs were estimated from the national standard of myeloid leukemia treatment,
which was developed and published by Russian Ministry of public health. At the
last stage sensitivity analysis was conducted. Exchange rate 1€ 42 RUB. RESULTS:
The cost of pharmacotherapy with azacitidine was 1 197 157 RUB (28 503€) and with
low dose cytarabine 22 841,51 RUB (544€). Total costs of treatment were 2 658
703RUB (63302 €) for azacitidine and 1 749 130 RUB (41646€) for low dose cytarabine.
Side effects treatment costs were about 40% of total costs for cytarabine, while for
azacitidine only about 14% of total costs. A cost-effectiveness ratio (cost per 1 year
gained) of azacitidine was 1 303 286 RUB (31030€) which is lower then the use of
cytarabine 1 366 507,73 RUB (32536€). Sensitivity analysis demonstrated stability of
results. CONCLUSIONS:Application of azacitidine for the therapy of acute myeloid
leukemia and MDS syndromes is dominant alternative of treatment from the phar-
macoeconomical perspective.
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OBJECTIVES: Melanoma is a particularly aggressive form of skin cancer, the inci-
dence of which continues to increase. Whilst no new therapies had been developed
for approximately 25 years, new treatments – including the immunotherapy ipili-
mumab – have been licensed. The objective of this study was to assess the cost-
effectiveness of ipilimumab in previously treated metastatic melanoma.
METHODS: A semi-Markov model, based around survival curves from the MDX-
010-20 trial, was constructed. Because of the unusual shape of the survival curve
(exhibiting a plateau of survival at around 15% of patients after an initial steep fall),
the survival data was split in to three sections, modelled using Kaplan-Meier data
(0-18 months), parametric curve fits (18-60 months) and registry data (60 months).
Utility, drug dosage and patient weight data were taken from the trial, while costs
were taken from published sources and NHS Reference Costs. RESULTS: Ipili-
mumab was projected to result in a substantial increase to life when compared to
best supportive care (2.77 vs 1.07 life years), with a correspondingly large increase
in quality-adjusted life years (2.06 vs 0.82). As a result of drug therapy, costs also
increased from £11,747 to £89,607, giving ipilimumab an incremental cost-effec-
tiveness ratio of £65,303 (excluding any vial sharing). Sensitivity analysis indicated
the greatest areas of uncertainty were the methods used to extrapolate of survival
curves beyond the 56-month trial data and the utility values used. CONCLUSIONS:
The modelling of survival curves should be tailored depending on the shape of the
data –parametric survival curve fitting may not always be appropriate. The results
of the model showed that ipilimumab has the potential to lengthen life substan-
tially (40.1 vs 11.4 months). From this, the degree of innovation (extent of survival
gain) is such that ipilimumab could be considered cost-effective under the NICE
End of Life guidance and Kennedy report as a ‘step-change’.
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OBJECTIVES: PALETTE was a phase III, randomized controlled trial of pazopanib
versus placebo in 369 patients with advanced/metastatic soft tissue sarcoma (STS)
who had received prior treatment with chemotherapy. Pazopanib improved pro-
gression free survival (PFS) vs. placebo (4.6 vs. 1.5 months, hazard ratio [HR]0.39,
p0.0001). Median overall survival (OS) was 12.6 vs. 10.7 months with pazopanib vs.
placebo (HR  0.87, p0.256). As PALETTE did not assess cost-effectiveness, the
objective of this evaluation was to assess the cost-effectiveness of pazopanib from
a UK health care system perspective. METHODS: A partitioned survival analysis
model was developed to estimate expected PFS, OS, lifetime costs of STS treatment,
and quality adjusted life years (QALYs) for patients receiving pazopanib, placebo,
trabectedin, or ifosfamide. Estimates of PFS/OS, incidence of adverse events, and
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